Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Revenues:
Product revenue, net	$ 606
Collaboration and license revenue	6,038	$ 5,128
Total revenues	6,644	5,128
Operating expenses:
Cost of sales	336
Research and development	60,067	30,645
Selling, general and administrative	31,541	15,021
Total operating expenses	91,944	45,666
Loss from operations	(85,300)	(40,538)
Interest and other income, net	3,371	413
Interest expense	(2,581)	(1,639)
Net loss	(84,510)	(41,764)
Net loss attributable to noncontrolling interest (SRX Cardio)	332	45
Net loss attributable to Portola	$ (84,178)	$ (41,719)
Net loss per share attributable to Portola common stockholders:
Basic and diluted	$ (1.28)	$ (0.74)
Shares used to compute net loss per share attributable to Portola common stockholders:
Basic and diluted	65,509,945	56,692,788